Your Article Summary
See Latest ArticlesCEL-SCI Signs Definitive Agreement to Raise $5 Million in Registered Direct Offering
CEL-SCI, 06/26/09
CEL-SCI Corporation, a late stage cancer immunotherapy company, announced that it has entered into a definitive agreement with one institutional investor to sell 12.5 million units, with each unit consisting of one of the Company's common shares and 0.67 warrants to purchase one share of common stock, for gross proceeds of approximately $5.0 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering.
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Covidien Announces Definitive Agreement to Sell U.S. Radiopharmacies
Covidien, 12/18/09
MediciNova and Avigen Stockholders Approve Merger
Avigen, 12/18/09
GlaxoSmithKline and NanoBio announce OTC licensing agreement for cold sore treatment
GlaxoSmithKline, 12/18/09